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Abstract  
The role of Nitric oxide, which is an important signalling molecule, has become an active and 
controversial area of research in cancer. Nitric oxide has been designated as “Double -edged sword” in 
Cancer as it has exhibited both pro-apoptotic and anti-apoptotic effects. Nitric oxide synthase (NOS) 
levels have been associated with contrasting effects of tumor suppression & tumor progression. The 
discovery of generation of NO in mammalian tissues and its biological role in cancer has thrown light 
into tumor biology research. Through various studies conducted, it has become clear that 
concentration and time dependent regulation of Nitric oxide lead to tumor growth, cytostasis and cell 
death .The regulation of tumor growth by Nitric oxide represents an important new dimension in 
cancer research and  understanding of mechanisms involved  behind this process at molecular and 
cellular level is a major area of concern which will open up new avenues in Cancer Research and may 
help to provide new and better therapeutic interventions in diagnosis, treatment and cure of Cancer.  
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Introduction 
In the year 1987, Nitric oxide was identified as 
Endothelium derived Relaxing factor (EDRF) 
by Ignarro et al [1] & Montana et al [2]. Nitric 
oxide is a highly reactive free radical due to the 
molecular arrangement which leaves an 
unpaired electron. The small size and 
lipophilicity are two properties due to which   
nitric oxide diffuses easily through the cell 
membrane (Kroncke 2001). This universal 
signalling molecule is involved in many 
physiological as well as pathological processes. 
Low or moderate NO levels were associated 
with immune function, blood flow, platelet 
aggregation, neurotransmission and memory. 
Increase production of Nitric oxide was found in 
inflammatory and immunological disorders, 
pain, neurological diseases, atherosclerosis and 
cancer [3].In the year 1992, Nitric oxide was 
awarded “the molecule of the year” and year 
1998 became remarkable when Noble prize was 
awarded together to Robert F. Furchgott, Louis J. 
Ignarro and Ferid Murad in Physiology or 
Medicine for their discoveries regarding nitric 
oxide as a signalling molecule in the 
cardiovascular system. 
Hibbs and co-workers demonstrated that 
Nitric oxide is the active factor responsible for 
the macrophage mediated killing of tumor cells 
in model systems [4].No being a pleiotropic 
molecule is capable of altering many cellular 
processes depending upon its rate of generation 
due to which its role in cancer development has 
become a contentious area of research despite 
the fact that the role of Nitric oxide has been 
established in human cancers as well as 
experimental models. Several studies were 
conducted and it was evident that, at very high 
production of NO, killing of cancerous cell 
occurs and at very low levels, is found to be 
responsible for tumor growth. However, at 
intermediate levels, Nitric oxide is found to 
protect cancer cells from apoptosis. Thus, Nitric 
Oxide is shown to be both pro-apoptotic and 
anti-apoptotic depending upon factors like flux, 
dose, specific cells involved as well as the redox 
state of those cells. While, Nitric oxide is being 
labelled as a causative agent in cancer, many 
experimental studies both in vitro and in vivo 
shows this molecule to be protective against 
many chemical species which is known to 
induce cancer. Thus, the multitude effects of 
Nitric oxide related to other aspects of tumor 
biology have been studied. Thus, evaluation of 
the mechanism of Nitric oxide at molecular 
level is required in order to exploit its potential 
as cancer therapy taking into account the tumor 
biology (processes involved like Angiogenesis, 
blood flow, metastasis, proliferation, apoptosis, 
immune system surveillance) which could help 
to initiate further studies in this direction. 
 
 
 
 
 
 
 
 
Figure 1 showing molecule of Nitric oxide. 
Nitric oxide synthase (NOS) 
enzymes  
Nitric oxide synthase is a haem protein which is 
similar to cytochrome P450. L-arginine is used 
as a substrate used during synthesis of nitric 
oxide which is converted to L-citrulline and this 
process is catalysed by an enzyme nitric oxide 
synthases. NO synthases are responsible for the 
synthesis of Nitric oxide from the substrate 
L-arginine. 
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Figure 2 Biosynthesis of Nitric oxide 
 
Isoforms of Nitric oxide synthase (NOS)- 
Nitric oxide synthase enzyme has three isoforms: 
NOS 1 or neuronal nitric oxide synthase (nNos). 
NOS 2 or inducible nitric oxide synthase (iNOS). 
NOS 3 or endothelial nitric oxide synthase (eNOS). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 showing (a) Inducible NOS (iNOS); (b) Endothelial NOS (eNOS); (c) Neuronal NOS (nNOS) 
 
These isoforms have been categorized as 
constitutive (both eNOS and nNOS) and 
inducible nitric oxide synthase 
(iNOS).Constitutive NOS(c NOS) is calcium 
dependent and produces low NO levels where as 
iNOS is calcium independent and generates high 
levels of NO. It is found that when cells are 
exposed to cytokines, high levels of NO are 
produced [5]. 
Inducible NOS (iNOS) - Inducible NOS is 
expressed mainly in macrophages, neutrophils 
and epithelial cells. This is governed by factors 
like lipopolysaccharides or cytokines. It has 
been found that the synthesis of iNOS can also 
be induced in glial cells, liver and cardiac 
muscle. 
Endothelial NOS (eNOS) – This is a 
constitutive isoform dependent and expressed in 
endothelial lining of blood vessels. This isoform 
of NOS elicit CGMP dependent smooth muscle 
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relaxation in smooth muscle cells of blood 
vessel which increases blood flow.  
Neuronal NOS (nNOS) – This is expressed 
constitutively in post synaptic terminals of 
neurons and is calcium dependent. Opening of 
voltage gated calcium channels results in 
membrane depolarization and which in turn 
activates nNOS [6]. 
All the three isoforms have been detected in 
tumors (Tozer and Everett 1997). NO produced 
endogenously had profound effects on tumour 
blood flow, angiogenesis and metastatic 
potential (Wink et al 1998) and was identified as 
an excellent target for cancer therapy. Still, the 
area of concern remains whether there is more 
therapeutic benefit by inhibiting NO production 
in tumors or by enhancing the production of 
Nitric oxide.  
Chemical biology of Nitric oxide 
The chemical reaction of Nitric oxide is based 
on its chemistry which occurs at different flux 
and concentration [7, 8].At low levels, NO was 
found to protect cell but in contrast, at higher 
levels, it is a known cytotoxin which has been 
implicated in tumor angiogenesis and 
progression [9].   
The biological reactions of NO are divided 
into three main pathways [10]. 
1) Diffusion- NO diffuses the cell membrane 
by simple diffusion and reacts with 
cellular components. Once inside the cell, 
it reacts with non-heme iron or quench 
tyrosyl radical of ribonucleotide reductase 
leading to the inhibition of DNA synthesis 
[11, 12 ]. 
2) N2O3 (nitrous anhydride) is formed by 
Auto-oxidation  
 
 
Nitrous anhydride is formed by 
combination of Nitric oxide and nitrogen 
dioxide. 
3) Peroxynitrite is formed by reaction with 
superoxide 
Peroxynitrite formed is not a free radical 
and is a potent oxidant which reacts with 
almost all biological molecules [13]. 
Combination of carbon dioxide with the 
peroxynitrite anion forms nitroso 
peroxycarbonate adducts which on 
decomposition forms NO3
−
 and CO2. 
 
 
Nitric oxide reacting with molecular 
oxygen, which is present in higher 
concentration than nitric oxide, to form 
peroxynitrite [14] takes place in aqueous 
or gaseous phase. NO2 is a stable product 
of NO oxidation in gaseous phase where 
as NO2 give rise to NO, NO3
−
 [15] in 
aqueous solutions.  
2NO+ O2    2NO2    NO- + NO3
- 
   ONOO- 
The nitroxyl anion (NO
-
) is found to be 
endothelium derived relaxing factor which is 
short lived and very reactive [16].  
The chemical biology of Nitric oxide is 
divided into two types of effect. 
1) Direct effect of NO 
2) Indirect effect of NO 
Direct effect of NO- This involves 
those chemical reactions in which NO is 
reacting directly with a biological target. 
For instance, low levels of NO can react 
directly with haem-containing proteins 
such as guanylate cyclase, 
oxyhemoglobin, and cytochrome p450 
which is responsible for the 
neuromodulatory effect of nNOS and 
vasodilatory effect of eNOS. 
At low concentration of NO, direct 
effects will predominate, while at higher 
concentration indirect effects mediated by 
NO/O2
-
 [17]. NO protects tissue from 
peroxide mediated damage by scavenging 
metal oxo species [18].This free radical 
reacts with non-heme iron at the active 
site and inhibit lipid oxygenase activity 
[19]. 
The toxic effects of NO involve its oxidation 
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products where as NO alone is not capable of 
DNA damage [20]. It was shown that on 
exposure to NO generating agents, p53 is 
induced in both RAW 264.7 macrophages and 
RINm5F cells [21]. P53 is a protein responsible 
for maintaining genome stability. On exposure 
to DNA damaging agent, rapid increase in p53 
level occurs. Generally, p53 has a short half life 
but DNA damage results in its accumulation in 
cells [22] which leads to DNA fragmentation 
and finally apoptosis. 
NO mediates DNA damage by 3 mechanisms: 
i. Formation of nitrosamines. 
ii. Inhibition of DNA lesion repair system 
which is a genotoxic mechanism. 
iii. Modification of DNA not directly by 
NO but by its oxidation products [23]. 
Indirect effects of NO- This involves those 
chemical reactions which are mediated by 
RNOS formed through reaction of NO either 
with O2 or with superoxide. These reactions 
require high local concentrations of NO, of 
which, NOS may be the sole biological source. 
Indirect effect of NO is further divided into: 
a) Oxidation 
b) Nitrosation 
Oxidation- Oxidation reaction is those where 
removal of electrons or hydroxylation reaction 
occurs, similar to those for (ROS) reactive 
oxygen species, leading to oxidative stress [24]. 
Nitrosation reaction- Nitrosation reaction is 
those in which RNOS donate NO to nucleophilic 
groups such as thiols and amines. Nitrosonium 
adducts formed in the biological systems are 
termed as nitrosative stress. 
Thus, a diverse range of chemical reaction 
producing uncontrollable result is undoubtedly 
balanced by both nitrosative and oxidative stress 
[25]. 
Genotoxic mechanisms of Nitric 
oxide 
The mechanism by which NO participate in 
genotoxic events involves the indirect chemistry 
of NO. For such event or reaction to occur, in 
vivo requires high local concentration of NO 
which is generated by iNOS. This would be 
reasonable to expect that sites of potential 
carcinogenic risk are those which inhibit 
prolonged expression of iNOS such as during 
chronic inflammation .Along with the formation 
of carcinogenic nitrosamines, NO increases the 
susceptibility of cells to other genotoxic agents 
which exhibit the indirect role of NO in 
genotoxicity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Potential genotoxic mechanisms of Nitric oxide 
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Figure 5 Factors regulating cancer biology 
 
Role of Nitric oxide in cancer 
biology 
Carcinogenesis is defined as a malignant 
transformation of a cell or group of cells. This 
process is divided into three stages: 
i. Initiation 
ii. Promotion 
iii. Progression 
Initiation phase involves modification of the 
genetic material of the cell due to single 
exposure to any carcinogenic agent which is 
irreversible. Promotion stage which is also 
irreversible involves multiple exposure to the 
promoter, alter gene expression and produces 
tumour. 
The complex role of NO in cancer biology is 
based on earliest studies on NO. 
(a) NO from macrophages were found to 
inhibit respiration in tumor cells [26, 27] 
while other studies indicated that through 
nitrosative process of NO, carcinogenic 
nitrosamines were derived from NOS 
[28]. 
(b) Later, it was found that RNOS reactive 
nitrogen oxide species derived from NO 
are carcinogenic. It may be due to 
alteration of DNA chemically as well as 
increasing the susceptibility to other 
genotoxic agent such as alkylating 
agents[29] and metals such as 
cadmium[30] 
(c) Some studies suggested that expression 
of NOS reduce metastasis while other 
studies suggested that such tumors which 
express NOS are more aggressive in 
vivo. 
Thus, parameters like Angiogenesis, blood 
flow, apoptosis, Metastasis, Immune 
surveillance are evaluated to explain the 
complex nature of NO in cancer. 
Anti-carcinogenic effect or Tumor suppressing 
effect of NO 
 
 
 
 
 
 
 
 
Figure 6 Cytostatic and cytotoxic mediated actions of NO 
 
In earlier studies, Seminal experiments from 
macrophages inhibit cellular respiration in 
target cell [31] but later reports demonstrated  
that NO derived from macrophages, Kupffer 
cells, natural killer cells and endothelial cells 
exhibited tumoricidal activity against many 
Inhibition of Respiration 
Iron metabolism is affected 
Inhibition of Ribonucleotide Reductase 
 
Formation of RNOS 
Damage to cellular components 
 
Cytostatic Cytotoxic 
Direct effect 
Nitric oxide 
Indirect effect 
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tumors [32].Thus, suggesting that NO tumor has 
a cytostatic and cytotoxic effect on tumor cells. 
 
Aconitase and ribonucleotide reductase are 
the two molecular targets which has been 
utilised in the cytostasis or cytotoxicity 
mediated by NO. Mitochondrial aconitase [33] 
is the first NO target associated with tumoricidal 
activity of macrophages. Mitochondrial 
aconitase and iron-responsive binding protein 
(IRB) found in the cytosol are two enzymes 
possessing aconitase activity .Studies implied 
that aconitase activity is modified by oxidation. 
This oxidation  process is mediated by 
superoxide and peroxynitrite  and to lesser 
extent by Hydrogen peroxide and oxygen, but 
not by NO [34].These findings suggest that 
indirect effects are responsible for aconitase 
inhibition  and direct effect of NO was studied 
through anaerobic solution of NO inactivated  
aconitase reversibly [35]. 
IRB protein regulates the transcription of iron 
responsive elements (IRE) which in turn 
regulates the transferrin receptor or ferritin. 
The IRB exists in two forms: 
1) Holoprotein- This has aconitase 
activity and cannot bind to the IRE. 
2) Apoprotein- This has no aconitase 
activity but can bind to the IRE. 
iNOS activity increases the cellular uptake of 
iron while nNOS activity enables the binding of 
IRB to IRE .In case of mitochondrial aconitase; 
superoxide and peroxynitrite inhibit the 
aconitase activity of IRB while NO does not 
[36]. 
Unlike superoxide or peroxynitrite, NO 
stimulates the binding of IRB to the IRE. 
Superoxide and peroxynitrite modify the IRB 
such that it cannot bind to the IRE effectively, 
by the oxidation of thiol group. These reactive 
species inhibit the protein irreversibly 
abolishing both aconitase activity and IRE 
binding. Thus, direct effects of NO would result 
in increased iron uptake where as indirect effect 
of NO or ROS result in decreased iron uptake. 
These direct and indirect effects are crucial in 
tumor growth as well as cytotoxic /cytostasis 
mechanisms mediated by the immune system 
against tumor cells. 
NO also affects iron metabolism protein 
which is affected by NO including reaction of 
NO with ferritin to form Fe-NO complexes. 
Ferrochelatase involved in the synthesis of 
heme protein is also inhibited by NO. Therefore, 
NO suppresses cellular respiration and shifts 
iron metabolism which is contributing to the 
cytostatic properties of NO. The cytostatic 
effect of NO is implicated by inhibition of the 
enzyme Ribonucleotide Reductase which leads 
to suppression of DNA synthesis.  This is due 
to reaction between NO and tyrosyl radical 
species formed in ribonucleotide reductase [37]. 
The viability of tumor lines were reduced on 
administration of Nitric oxide donors [38] by 
deleting intracellular stores of GSH and making  
other cells susceptible to other toxic 
mechanisms[39].When cells were treated with 
NO donors with short half –lives and exposed to 
high fluxes of NO for short periods of time, 
cells exhibited increased sensitivity to NO. 
Differences in proliferation were shown in 
presence or absence of intracellular GSH, when 
longer acting NO donors were 
administered[38].Thus, high concentration of 
NO may result in the formation of RNOS  
which mediates cell death, while lower fluxes 
mediate cytostasis by interacting with  
metal/tyrosyl radicals. Macrophages in direct 
contact with tumor cells is expected to generate 
4-5µM  NO [40] and thus mediate indirect 
effects ,whereas tumor cells farther away would 
experience lower fluxes of NO associated with 
direct effects. 
The tumoricidal role of NO has been derived 
invitro; evidence in tumor bearing animals 
suggests that NO derived from leucocytes may 
have an antitumor role. Melanoma cells 
transfected with or stimulated to express iNOS 
show reduced cell growth invitro and limited 
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tumorigenesis and metastasis in 
vivo[41-44].These observations indicate that 
NO donors inhibit angiogenesis, tumor growth, 
and metastasis [45]. 
Expression of iNOS is suppressed in some 
tumors. Macrophages harvested from tumor 
bearing animals exhibit a reduced ability to 
produce NO and diminished tumoricidal 
activity[46-48].Several studies exhibited 
suppressed expression of  iNOS in 
macrophages from tumor bearing mice, which is 
due to systemic formation of tumor derived 
suppressor agents such as IL-10, TGF-β1,PGE2 
[49-51].This study suggests a relationship 
between NO production and tumoricidal 
activity. 
Another consequence of NO production is 
apoptosis. Reduced expression of iNOS 
involves apoptotic events within growing tumor 
[52]. Mastocytoma cells [53], Sarcoma cells [42, 
54], L929 cells [54, 55] and melanoma cells 
[43] are these cells which undergo extensive 
apoptosis upon exposure to NO, while other 
tumor cell lines such as A549 undergo limited 
apoptosis when exposed to chemical NO donors 
[56].The lymphocyte undergoing apoptosis was 
found to present phosphotidyl serine on their 
plasma membrane and macrophages are then 
stimulated to phagocyte these lymphocytes [57]. 
Phosphatidic acid suppresses the activity of  
iNOS both invitro[58,59] and in peritoneal 
macrophages from tumor bearing animals at 
transcriptional level[59].Thus, this leads to the 
further possibility that apoptosis and subsequent 
presentation of phosphotidyl serine may reduce 
NO generated from macrophages and results in 
reduction of antitumor activity within a given 
tumor. 
NO was found to have potent influence on the 
metastatic potential of cells including motility, 
adhesion and invasion (reviewed by Williams 
and Djamgoz 2005). Treatment of metastatic 
disease is a major clinical problem and reports 
suggest that Nitric oxide produced 
endogenously by tumor cells may reduce their 
metastatic potential. Wei et al (2003) showed 
that iNOS expression in stroma supplying 
tumors slowed down their growth dramatically 
and reduce metastasis. The adhesion of tumor 
cells which is blocked to the venular side of 
microcirculation  is another metastatic 
mechanism of NO.NO was shown to inhibit 
tumor cells adhesion [60] in a way similar to 
inhibition of leukocyte adhesion for ischemia 
reperfusion injury [61-63]. Thus, data suggested 
that low levels of NO produced by the 
endothelium will reduce metastasis to tissues 
such as lung. Inhaled Nitric oxide did not 
prevent the metastasis of melanoma cells to the 
lung [64].Other reports suggested that NO 
produced by endothelium of liver prevents 
metastasis of lymphoma cells [65] while NO 
produced in the vasculature of brain limits the 
spread of colon cancer to that tissue [66].In 
addition, NO secreted by microglial cells also 
suppress the spread of cancer to the brain [66]. 
Tumor promoting effect or Pro-carcinogenic 
effect of NO 
 
 
 
 
 
 
Cytostatic action/Cytotoxic     Promotes tumor growth 
Figure 7 Conflicting effects of NOS expression 
 
In contrast to the antitumor role of NO, NO 
was found to be an important mediator of tumor 
growth. The multistage carcinogenesis model 
was evaluated. NO was reported to act in other 
stages of cancer growth in addition to initiation. 
The examples are 
1) NO formed endogenously caused the 
neoplastic transformation of   C3H 
10T1/2 mouse fibroblasts cells [67]. 
2) Another example is NO mediated 
secretion of mucin by colonic 
adenocarcinoma cells, which was 
NOS expression 
Increase NOS expression Decrease NOS expression 
 Rath M. et al. American Journal of Cancer Biology 2013, 1:38-56 
  
Ivy Union Publishing | http: //www.ivyunion.org September 30, 2013 | Volume 1 | Issue 2  
Page 9 of 19 
consider to protect tumor has a role in 
promoting tumor [68]. 
3) Human adenocarcinoma (DLD-1) and 
murine mammary carcinoma (EMT-6) 
expressing iNOS showed inhibited 
growth in vitro. 
Contrary to melanoma which expresses NOS, 
these cell lines are more aggressive when 
transplanted into mice [69, 70].This suggests 
that NO produced by these cells promote tumor 
growth. Other studies suggest that 5-FUDR 
activity in colon cancer may be due to reduction 
in iNOS expression and may account for the 
activity of chemotherapeutic drug [71]. 
Both constitutive and inducible forms of NOS 
were found to be present in tumors. Both the 
isoforms of NOS have been detected in human 
breast tumor [72],cervical tumors [73], tumors 
associated with CNS [74],colon [75] and Head 
and neck cancer [76]. Cytokine stimulation 
showed expression of iNOS in mammary 
carcinoma, melanoma and human colon 
adenocarcinoma as well as in breast cancer 
patients. All these data support the evidence that 
NO may play a critical role in growth and 
spread of tumors. 
Another important mechanism of NO 
involved in tumor progression is regulation of 
Angiogenesis. Angiogenesis is defined as a 
process where tumor cells excrete certain 
protein that stimulates blood vessel growth into 
and around tumors. The tumor Keeps on 
growing, and eventually reaches a size where 
additional vasculature is required in order to 
maintain continued growth. Tumor expansion 
was found to be impossible without vascular 
proliferation (Folkman 1990).NO shown to be 
an important mediator of angiogenesis in 
various in vivo and invitro model systems. 
(Guoetal 1995, Murohara et al 1998, Jadeski & 
Lala 1999, Ziche & Morbidelli 2000; Kashiwagi 
et al 2005). Higher concentration of NO was 
found to be anti-angiogenic in various reports 
(Pipeli-synetors 1994; Lare & Ma 1996; Ray 
chaudhary et al 1996; Rowell et al 2000). It is 
well established that growth factors such as 
VEGF (Vascular Endothelial Growth Factor), 
Fibroblast growth factor (FGF), and Platelet 
derived growth factor are stimulators of 
angiogenesis. Angiogenesis process requires 
three processes which are initiated when VEGF 
binds to specific receptors on vascular 
endothelium. 
1) Increased vascular permeability leads to 
formation of fibrin matrix which acts as a 
scaffolding for endothelial cells 
migration. 
2) Endothelial proliferation and migration 
into the matrix is guided by cytokine 
stimulation. This process involves other 
co factors such as TNFα, TNFβ, bFGF        
and angiogenic activity of some of these 
factors are regulated by NO [77]. 
3) Hyperpermeability of vascular 
endothelium that is stimulated by VEGF 
occurs via stimulation of NO synthesis 
[78]. 
The following observations were noted which 
support the evidence for pro-angiogenic action 
of NO. 
1) When glioblastoma and hepatocellular 
carcinoma cell lines were exposed to NO 
donor compounds (SNAP and 
NOR3).There was increase in VEGF 
production by stabilising m RNA levels 
[79]. 
2) When angiogenesis process is stimulated 
by substance P, use of NO donors leads 
to increase angiogenesis in the cornea 
pocket assay [80]. 
3) The in vitro proliferation coronary post 
capillary endothelial cells are stimulated 
by use of NO donors [81]. 
4) DLD1, the human colon tumor line 
which was incorporated with Nitric oxide 
synthase gene, grew more quickly and 
was better vascularised than the parent 
cell line [69]. 
There are enough of data to indicate that NO 
may actually down regulate angiogenesis. 
1) Arterial smooth cells produce VEGF 
which is down regulated by NO. The 
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inhibition occurs by inhibition of AP1 
binding to the VEGF promoter [82]. 
2) When exposure to exogenous NO took 
place, production of VEGF and its 
receptors were down regulated in exvivo 
perfused lungs and angiogenesis is 
inhibited in the chick corioallantoic 
membrane. Receptors were up regulated 
when NO synthase inhibitors were used 
[83, 84]. 
3) When animals are administered NO 
donor drugs, primarily tumor growth and 
metastatic frequency are lowered in the 
Lewis lung tumor model [45]. 
4) When NO donor drugs are administered 
proliferation and migration of endothelial 
cells is inhibited in vitro [85, 86]. 
Results from the tumor models suggest that 
NO stimulates angiogenesis. Though the data 
obtained from Lewis lung tumor model are 
difficult to interpret as the angiogenic process is 
not measured directly and due to administration 
of NO donor, hypotension was induced which 
made the tumor  hypoxic [87].This slows down 
the growth of primary tumors.The discrepancies 
of the data in other model systems depends on 
factors like: 
1) Environment in which cell were exposed 
to NO. 
2) Types of cells exposed to NO 
3) Presence or absence of other co factors 
involved in angiogenic process. 
Another important mechanism by which NO 
exhibits pro-carcinogenic effect is by 
modulating the production of Prostaglandins. 
PGE2 production was shown to increase by NO 
which increases the blood supply of the tumor 
[46, 88]. NO enhances the Prostaglandin 
synthase activity [89] and studies have been 
conducted which suggest that PG synthase 
production has been favoured by shifting the 
balance in arachidonic acid metabolism and 
simultaneously limiting the lipoxygenase 
products. PGE2 was shown to suppress the 
NO-dependent macrophage tumor vasculature 
which promotes tumor growth by facilitating 
angiogenesis [90, 91].The hypothesis that 
enhanced permeability take up higher level 
nutrients which promotes tumor growth [92] 
failed to provide an explanation as studies have 
shown that nutrients like (glucose, oxygen) are 
not dependent on vascular permeability to a 
great extent [93] and the mechanism was found 
to be indirect one. The most potential 
mechanism is that NO which causes PGE2 
activation in turn suppresses the NO production 
and tumoricidal activity of macrophages while 
facilitating angiogenesis. 
Systemic effect of NO also involves 
suppression of proliferation and infiltration of 
leucocytes which is relevant in cancer biology. 
Studies indicates that T cell proliferation is 
suppressed by NO compromising the antitumor 
response of the host [47, 94].When NOS 
inhibitors were administered ,there was 
increased activity of lymphocytes activated 
killer cells, thus limiting tumorignesis [91].Thus, 
this study indicates that NO is essential in 
controlling the proliferation of 
tumor-infiltrating T-cells as well as at more 
distant sites. 
Several studies done have reported that tumor 
cells producing  NO may prevent infiltration of 
leucocytes .One of the study indicated that 
inhibitor effect causes greater infiltration of 
leucocytes in tumor [47].Another study was 
done where systemic LPS administration causes 
leukocyte adhesion in normal vasculature  but 
not in tumor vascular suggesting that NO was 
released from tumor cells to prevent adhesion 
[78]. During Ischemia perfusion injury in which 
in which leukocyte infiltration is stimulated was 
suppressed by NO donors [95]. All these studies 
indicated that NO along with increasing the 
blood supply also down regulates expression of 
adhesion molecules such as VCAM which is 
important for inflammatory  and immune cell 
adhesion to vascular endothelium [96]. In this, 
radiation balances the process in favour of the 
immune system. 
Hence, the tumor suppressing and tumor 
promoting roles of NO can be described as both 
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direct and indirect effects. Low concentration of 
NO prevents binding of tumor cells to the 
endothelium mediated by direct effect. Other 
direct effects of NO also include prevention of 
leukocyte infiltration, suppression of T-cell 
proliferation, increase vascular permeability and 
angiogenesis. Whereas, the genotoxic effect of 
NO are mediated by indirect effects but the 
concentration of NO, where pro- to anti- 
malignant activity occurs, and which varies 
from one tumor type to another has not been 
defined. Thus, the amount and flux dictate both 
direct and indirect effects of NO, out of which 
amount is the important determinant which 
judges whether NO promotes or inhibits tumor 
growth. 
Therapeutic potential of NO 
The therapeutic potential of NO is explored 
by two opposite NO targeted strategies which 
will be difficult to interpret as different NO 
level will have variable consequences for 
different tumors as well as normal cells. 
1) Suppression of endogenous production of 
NO. 
2) Overproduction or over expression of 
NO. 
 
 
 
 
 
 
 
 
 
Figure 8 Potential of Nitric oxide as an anticancer agent 
Suppression of endogenous 
production of NO  
Kennovin et al 1994 showed that chronic 
administration of a non-isoform-specific 
L-arginine analogue causes inhibition of NOS 
in-vivo and resulted in regression of tumor 
growth in mice and rats. When specific iNOS 
inhibitors were administered to mice bearing 
different tumor types, tumor growth inhibition 
was found to be dependent on constitutive level 
of iNOS expression. Tumors which were 
expressing iNOS or genetically engineered to 
express iNOS showed growth inhibition where 
as growth of the parental, 
NOS-iNOS-expressing cell line was not affected 
by drug (Thomsen et al 1997). Thus, these 
studies confirmed that the dominant role of 
endogenous NO production in tumors, 
regardless of the iNOS isoform involved, is to 
promote growth, rather than to strengthen host 
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defence mechanisms that inhibit growth. 
Kennovin et al 1994 demonstrated that in 
order to suppress the tumor growth, long term 
administration of NOS inhibitors are required 
but the withdrawal of NOS inhibitors results in 
rapid resumption of normal growth rate. Babal 
et al 1997 and pechanova et al 2004 showed that 
L-NAME causes a variety of undesirable 
cardiovascular changes including myocardial 
fibrosis and serious hypertension(Kanagy 1997) 
210 mm Hg systolic after 21 days compared 
with normal value of ~ 140 mm Hg in a rat 
model at a dose lower than required for tumor 
growth inhibition. Atherosclerosis developed 
when L-NAME was administered which caused 
leukocyte to get attached with an arterial 
endothelium (Nabah et al 2005). Hence, chronic 
administration of non-specific NOS inhibitor 
does not seem to be a viable option for 
treatment in elderly cancer patients. The use of 
iNOS specific inhibitor can be used in such case 
because it avoids cardiovascular effects as iNOS 
does not affect NO generation in normal 
vascular architecture but it was found that this 
treatment option is viable only against tumors 
that express high levels of iNOS (Thomsen et al 
1997) and Franchi et al 2005 demonstrated that 
even after using iNOS specific inhibitor against 
those tumors expressing high levels of iNOS but 
suppression of growth was not there in all 
regions within the tumor. 
Overproduction of NO 
Nitric oxide over expression can be evaluated 
as a therapeutic strategy through pro-apoptotic, 
antimetastatic, radio sensitizing and chemo 
sensitizing activities. 
Activity as a single agent- The cytotoxic 
effect of NO to cancer cells is mediated by the 
generation of pro-apoptotic intermediates such 
as peroxynitrite and N2O3(Lechner et al 2005) 
and may inhibit DNA repair enzyme including  
poly(ADP-ribose) polymerase (Sidorkina et al 
2003). The ideal way to generate high 
concentration of NO in cancer cells is iNOS 
gene transfer techniques. Juang et al 1997, 1998 
used a murine melanoma cell line in vitro to 
transfer iNOS, then these cells were implanted 
in mice tumors, it was found that tumors grew 
more slowly and were less likely to metastasize 
than uninfected cells. Solar et al 2000 did in 
vivo transfection study where naked iNOS DNA 
injection in mouse thyroid cancer model where 
significant growth inhibition was found. One of 
the studies where liposomal vector was used to 
deliver a plasmid containing iNOS determined 
by constitutive or inducible promoters and 
inhibition of tumor growth was seen in syngenic 
mouse tumor and xenograft model (Worthington 
et al 2002, 2004, 2005).Application of NO over 
expression as a single modality fails to exploit 
its radio and chemo sensitizing potential. There 
has been evidence that pro-apoptotic activity of 
NO can be enhanced by using other classes of 
anticancer agents. Recent study was conducted 
using a breast cancer cell line which 
demonstrated NO induced apoptosis, when 
inhibitor of farnesyltransferase was added, but 
no effect was seen in breast epithelial cells 
(Pervin et al 2001). 
Radio sensitizing activity- NO was 
demonstrated to be a potent radio sensitizer in 
bacteria and mammalian cells 
( Howards-Flanders 1957; Gray et al 1958; 
Dewey 1960) soon after the demonstration of  
oxygen effect in radiation biology (Gray et al 
1953).The importance of NO as a radio 
sensitizer was rediscovered (Mitchell et al 
1993,1996,1998; Janssens et al 1999).NO was 
produced by several mechanisms and it was 
shown that higher concentration in the micro 
molar range enhanced the in vitro radio 
sensitizing ratio of 2.1-2.5 as effective as 
oxygen and much more effective as any radio 
sensitizing drugs which has been tested in vivo. 
Griffin et al 1996 obtained similar results using 
NO donors. Recently gene therapy strategies 
have been used to radiosensitize tumor cells 
both in vivo and in vitro. Matsumoto et al 2001 
demonstrated radio sensitizing effect of NO at 
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high concentration but at much lower levels 
leads to a radio protective bystander effect. 
Thus, a great therapeutic potential lies in the 
fact when high concentration is achieved in 
tumors while maintaining the lower 
concentration in normal tissue. 
NO plays a major role in radiation-induced 
bystander mechanisms in addition to radio 
sensitization. Shao et al 2003;Sokolov et al 
2005 indicated radiation induced NO generation 
which is contributing to the bystander effect by 
showing Nitric oxide specific scavenger present 
in culture medium, reduced cellular damage in 
the surrounding cell population. 
Chemo sensitizing activity- Kroncke 2001; 
Kroncke et al 2002 demonstrated that NO is 
capable of nitrosating or oxidizing Zn 
finger-containing proteins leading to the 
denaturation. Earlier studies have shown that Zn 
finger-containing DNA repair proteins including 
Fpg (Wink & laval 1994), DNA ligase 
(Graziewicz et al 1996) and 
06-methylguanine-DNA-methyl transferase 
(Laval and wink 1997) can be inhibited by NO 
donor compounds in vitro and in vivo. 
There has been evidence which proves that 
levels of NO directly mediate the effects of 
some of the cytotoxic agents like cisplatin (Son 
& Hall 2000) and 5-Fluorouracil (Oshima et al 
2001).High concentration of NO was found to 
have chemo sensitizing activity. Wink et al 1997 
showed that when V79 lung fibroblasts were 
treated with either NO saturated medium for 30 
minutes or NO donor drugs for 60 minutes, 
resulted in sensitization with subsequent 
cisplatin exposure. Another study was carried 
out by Azizzadeh et al 201 where similar results 
were obtained in Head and neck squamous 
carcinoma cells using different NO donors, but 
in this case only long acting donors were  
effective as chemo sensitizer. Liu et al 2004 
showed that class of NO releasing agent 
(diazeniumdiolates) enhanced cisplatin 
cytotoxicity in rat liver epithelial cells line by 
increasing intracellular concentration of 
cisplatin via activation of MAP kinase pathways. 
When MCF-7 human breast cancer cells were 
exposed in vitro to NO gas, NO donors (when 
given before doxorubicin) or iNOS gene transfer 
along with doxorubicin, NO was found to 
chemo sensitize. Jea et al 2003 showed that NO 
donor (nitrosocaptopril) enhanced the 
transmembrane uptake of taxol and was found to 
increase the cytotoxic effect in two prostate 
cancer cell lines in vitro but none of the effect 
was seen in neuroblastoma cell lines. Role of 
P-glycoprotein mediated drug transport was 
suggested. 
Konovalova et al 2003 studied the in vitro 
chemo sensitization of NO. The group used 
combination of NO donor 3, 3-Bis 
(nitroxymethyl) oxetane with cyclophosphamide 
and doxorubicin in mouse models of lung cancer, 
melanoma and leukemia. This showed 
impressive results by prolonging survival of 
leukemia bearing animals as compared to 
cytotoxic drugs alone. NO donors in 
combination with cyclophosphamide enhanced 
inhibition of metastasis from subcutaneously 
implanted melanomas compared with 
cyclophosphamide alone. NO therapy inhibited 
the development of resistance to 
cyclophosphamide in leukemic cells. This group 
reiterated the potential of NO therapy and 
further studies have been instigated in this area. 
Though, NO acts as a chemo sensitizer in 
combination with cytotoxic agents, but there are 
exceptions. iNOS derived NO was found to 
confer resistance in a rat glioma cell line against 
chloroethylnitrosourea (Yen et al 2001) via 
mechanism involving S-nitrosoglutathione (Yen 
et al 2004), a potent antioxidant obtained due to 
interaction between NO and glutathione. Further, 
full understanding of mechanisms involving the 
chemo sensitizing activity of NO needs to be 
evaluated. 
Discussion 
NO level has a fundamental aspect in cancer 
biology .The multidimensional roles of NO in 
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cancer are based on timing, location and 
concentration. When a tissue is exposed to high 
level of NO for prolonged period either during 
chronic inflammation or environmental 
exposure, accumulate mutations due to NO or 
mediated by genotoxic agents. As the tumor 
progresses, NO derived from iNOS kill tumor 
cells. Although, NO can mediate capillary 
leakiness, stimulate angiogenesis and limit 
infiltration of leucocytes but it has been found 
that NO could also limit metastasis and could 
cause apoptosis of tumor cells. This dichotomy 
of Nitric oxide has been a great challenge for 
scientists working in cancer therapy. Thus, the 
timing, and location of NO is important 
determinant in cancer cell biology. This is also 
important to evaluate the use of systemic NOS 
inhibitors and NO donors which involves a 
combined properties (chemical, biochemical, 
toxicological & physiological) properties of 
NO. 
Hence, NO has a tremendous potential as an 
anticancer agent if targeted to tumor at high 
concentration. NO donors have shown many 
anticancer effects invitro but the dose which 
required in vivo resulted in unacceptable 
systemic effects such as hypotension which 
made it unsuitable for clinical use.NOS 
activation confined to tumor volume and gene 
therapy combined with NO generating 
capability proves to be a therapeutic gain. More 
specific targeting, gene activation combined 
with radiotherapy and chemotherapy will result 
in effective tumor control but we need to 
overcome problem or search a remedy for 
problems associated with gene therapy such as 
delivery, tumor targeting and toxicity of viral 
vectors which will allow further exploitation of 
NO. Nitric oxide being a mediator of cancer has 
led investigators to develop strategies by 
manipulating in vivo production and exogenous 
delivery of this molecule as therapeutic gain. 
Attempts to develop NO-based cancer therapy 
are still in budding stages, and an extended 
understanding of the levels of NOS expression, 
timing, and the concentrations of NO produced 
in the tumor vasculature which is key to the 
development of novel strategies for diagnosis, 
prevention, treatment and cure of cancer. 
Understanding tumor biology at molecular and 
cellular level which has been affected by NO 
will allow researchers to exploit the potential 
anticancer properties of drugs interfering with 
NO metabolism. 
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